0000899243-22-020078.txt : 20220531
0000899243-22-020078.hdr.sgml : 20220531
20220531100210
ACCESSION NUMBER: 0000899243-22-020078
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220531
FILED AS OF DATE: 20220531
DATE AS OF CHANGE: 20220531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fuhrman Alan
CENTRAL INDEX KEY: 0001303521
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39425
FILM NUMBER: 22980997
MAIL ADDRESS:
STREET 1: C/O AMBIT BIOSCIENCES CORPORATION
STREET 2: 11080 ROSELLE STREET
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001651431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 364813934
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 978-503-2124
MAIL ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-31
1
0001651431
Checkmate Pharmaceuticals, Inc.
CMPI
0001303521
Fuhrman Alan
C/O CHECKMATE PHARMACEUTICALS, INC.
245 MAIN STREET, 2ND FLOOR
CAMBRIDGE
MA
02142
1
0
0
0
Stock Option (Right to Buy)
3.93
2022-05-31
4
D
0
246671
D
2031-10-27
Common Stock
246671
0
D
Stock Option (Right to Buy)
6.27
2022-05-31
4
D
0
10030
D
2031-06-16
Common Stock
10030
0
D
Stock Option (Right to Buy)
2.62
2022-05-31
4
D
0
22736
D
2029-06-12
Common Stock
22736
0
D
At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.
/s/ Kleem Chaudhary, attorney-in-fact
2022-05-31